Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors and to Serve as A Member of the Nominating Committee, Effective June 1, 2024

Keros Therapeutics, Inc. announced that it appointed Jean-Jacques Bienaimé to its Board of Directors, effective June 1, 2024. Mr. Bienaimé served as the Chief Executive Officer of BioMarin Pharmaceutical Inc. from May 2005, and as the Chairman from June 2015, until his retirement from BioMarin in December 2023. From November 2002 to April 2005, Mr. Bienaimé served as the Chairman, Chief Executive Officer and President of Genencor, Inc., a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics.

Prior to Genencor, Mr. Bienaimé served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporation, an immunology-focused biotechnology company, from 1998 to late 2002, becoming President in 1998 and Chief Executive Officer in 1999. Mr. Bienaimé also held several senior management positions at Rhône-Poulenc Rorer Pharmaceuticals (now Sanofi-Aventis) from 1992 to 1998, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaimé worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator (t-PA) for the treatment of heart attacks.

Mr. Bienaimé currently serves on the board of directors of Incyte Corporation and Immunome, Inc., as well as serving on the board of directors of a private biotechnology company. Mr. Bienaimé received an M.B.A. from the Wharton School at the University of Pennsylvania and a degree in economics from the École Supérieure de Commerce de Paris. The Board also appointed Mr. Bienaimé to serve as a member of the Nominating Committee.

Following Mr. Bienaimé?s appointment to the Nominating Committee, the membership of the three standing committees of the Board is as follows: Audit Committee: Mary Ann Gray (chair), Nima Farzan, Julius Knowles. Compensation Committee: Carl Gordon (chair), Mary Ann Gray, Ran Nussbaum, Alpna Seth. Nominating and Corporate Governance Committee: Tomer Kariv (chair), Jean-Jacques Bienaimé, Nima Farzan, Julius Knowles.